 The objective of this study is to test the hypothesis that INTERCEPT Blood System for platelet components stored for 6 or 7 days after INTERCEPT Blood System treatment retain sufficient viability for therapeutic efficacy. The post-infusion recovery and lifespan of autologous INTERCEPT Blood System for platelet components in 35 plasma65 InterSol Test platelets stored for 6 or 7 days will be measured in comparison to fresh autologous radiolabeled platelets Control platelets according to FDA guidance for platelet testing FDA 1999. Recovery and lifespan results between components stored for 6 and 7 days will also be assessed. 